| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.JCP.0000203196.65710.2B |
| P698 | PubMed publication ID | 16633140 |
| P2093 | author name string | Hsien-Yuan Lane | |
| Yi-Ching Liu | |||
| Yue-Cune Chang | |||
| Chieh-Liang Huang | |||
| Chung-Ta Lu | |||
| Wen-Ho Chang | |||
| Po-Lun Wu | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | weight gain | Q3403879 |
| P304 | page(s) | 128-134 | |
| P577 | publication date | 2006-04-01 | |
| P1433 | published in | Journal of Clinical Psychopharmacology | Q6294969 |
| P1476 | title | Risperidone-related weight gain: genetic and nongenetic predictors | |
| P478 | volume | 26 |
| Q34719766 | 5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies |
| Q37719385 | 759C/T Variants of the Serotonin (5-HT2C) Receptor Gene and Weight Gain in Children and Adolescents in Long-Term Risperidone Treatment |
| Q47348196 | A pharmacogenomic study revealed an association between SLC6A4 and risperidone-induced weight gain in Chinese Han population |
| Q55342505 | A preliminary study of association of genetic variants with early response to olanzapine in schizophrenia. |
| Q48304926 | Association Between 5-HTR2C -759C/T (rs3813929) and -697G/C (rs518147) Gene Polymorphisms and Risperidone-Induced Insulin Resistance Syndrome in an Indian Population |
| Q93185385 | Association between polymorphisms of LEP, LEPR, DRD2, HTR2A and HTR2C genes and risperidone- or clozapine-induced hyperglycemia |
| Q36747019 | Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population |
| Q46117105 | Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotic treatment |
| Q34006864 | Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles |
| Q37963571 | Atypical antipsychotic-induced weight gain: insights into mechanisms of action |
| Q28079227 | CYP2D6 polymorphisms and their influence on risperidone treatment |
| Q47161187 | Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children |
| Q38154911 | Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy |
| Q37793826 | Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses |
| Q37254782 | Drug-induced hyperphagia: what can we learn from psychiatric medications? |
| Q37422493 | Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release. |
| Q34273354 | Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. |
| Q34329113 | Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study |
| Q33408581 | Genetics of weight gain associated with antipsychotic medications |
| Q36950578 | HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis |
| Q38242739 | HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis |
| Q38170458 | Individualizing clozapine and risperidone treatment for schizophrenia patients |
| Q24610124 | Management of antipsychotic-related weight gain |
| Q36941595 | No Association between Serotonin Receptor 2C-759C/T Polymorphism and Weight Change or Treatment Response to Mirtazapine in Korean Depressive Patients. |
| Q38842714 | Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis |
| Q37917782 | Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review. |
| Q34676533 | Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction |
| Q36840610 | Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research |
| Q37076472 | Pharmacogenetics in psychiatry: are we ready for widespread clinical use? |
| Q36530878 | Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents |
| Q35237129 | Pharmacogenetics of antipsychotic-induced side effects |
| Q37926893 | Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. |
| Q33836837 | Pharmacogenetics of antipsychotics |
| Q38074712 | Pharmacogenetics of clinical response to risperidone. |
| Q37220366 | Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications |
| Q37952823 | Pharmacogenetics of response to antipsychotics in patients with schizophrenia |
| Q38086817 | Pharmacogenetics of risperidone: a systematic review of the clinical effects of CYP2D6 polymorphisms |
| Q38217628 | Pharmacogenetics of second-generation antipsychotics |
| Q92255814 | Pharmacogenomic Characterization in Bipolar Spectrum Disorders |
| Q40255006 | Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients |
| Q90294280 | Preclinical and Clinical Sex Differences in Antipsychotic-Induced Metabolic Disturbances: A Narrative Review of Adiposity and Glucose Metabolism |
| Q35145284 | Risperidone induced weight gain leading to benign intracranial hypertension |
| Q37725986 | Risperidone-Induced Adverse Drug Reactions and Role of DRD2 (-141 C Ins/Del) and 5HTR2C (-759 C>T) Genetic Polymorphisms in Patients with Schizophrenia. |
| Q36556433 | Risperidone-associated adverse drug reactions and CYP2D6 polymorphisms in a South African cohort |
| Q34413008 | Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene |
| Q36441507 | Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain |
| Q33660225 | Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. |
| Q48107672 | The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. |
| Q46716221 | The role of genetic variation across IL-1β, IL-2, IL-6, and BDNF in antipsychotic-induced weight gain |
| Q37960512 | Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia |
| Q38838191 | Weight gain with add-on second-generation antipsychotics in bipolar disorder: a naturalistic study |
Search more.